Consequently, with the miR-29a effects in fibrosis, Chen et al. [164] reported in type 2 diabetes in db/db mice anti-inflammatory and antifibrotic functions of miR-29b, with results associated with NF-κB-driven renal inflammation and T-bet/Th1-mediated immune response. Here, NFKB1 is linked to inflammation.